Download
fmed-08-663258.pdf 882,16KB
WeightNameValue
1000 Titel
  • Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports
1000 Autor/in
  1. Chehade, Hassib |
  2. Guzzo, Gabriella |
  3. Cachat, Francois |
  4. Rotman, Samuel |
  5. Teta, Daniel |
  6. Pantaleo, Giuseppe |
  7. Sadallah, Salima |
  8. Sharma, Amita |
  9. Rosales, Ivy A. |
  10. Tolkoff-Rubin, Nina |
  11. Pascual, Manuel |
1000 Verlag
  • Frontiers Media S.A.
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-26
1000 Erschienen in
1000 Quellenangabe
  • 8:663258
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-28
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fmed.2021.663258 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350112/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:p>Acute post-infections glomerulonephritis (APIGN) is a frequent cause of glomerulonephritis and represents the most common cause of acute glomerulonephritis in children. It can evolve to severe acute renal failure and chronic kidney disease or even end-stage kidney disease. The precise pathophysiological mechanisms of APIGN are still incompletely understood. The implication of the alternative complement pathway and the potential benefits of C5 blockade have been recently highlighted, in particular in the presence of a C3 Nephritic Factor (C3Nef), anti-Factor B or H autoantibodies. We report two children with severe APIGN, successfully treated with eculizumab. The first patient presented a severe form of APIGN with advanced renal failure and anuria, associated with a decreased level of C3 and an increased level of soluble C5b-9, in the presence of a C3NeF autoantibody. The second case had a severe oliguric APIGN associated with low C3 level. Kidney biopsy confirmed the diagnosis of APIGN in both cases. Eculizumab allowed full renal function recovery and the avoidance of dialysis in both cases. In conclusion, the alternative and terminal complement pathways activation might be common in PIGN, and in severe cases, eculizumab might help.</jats:p>
1000 Sacherschließung
lokal Medicine
lokal terminal complement pathway blockage
lokal case report
lokal post-infectious glomerulonephritis
lokal eculizumab
lokal anti-c5 monoclonal antibody
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q2hlaGFkZSwgSGFzc2li|https://frl.publisso.de/adhoc/uri/R3V6em8sIEdhYnJpZWxsYQ==|https://frl.publisso.de/adhoc/uri/Q2FjaGF0LCBGcmFuY29pcw==|https://frl.publisso.de/adhoc/uri/Um90bWFuLCBTYW11ZWw=|https://frl.publisso.de/adhoc/uri/VGV0YSwgRGFuaWVs|https://frl.publisso.de/adhoc/uri/UGFudGFsZW8sIEdpdXNlcHBl|https://frl.publisso.de/adhoc/uri/U2FkYWxsYWgsIFNhbGltYQ==|https://frl.publisso.de/adhoc/uri/U2hhcm1hLCBBbWl0YQ==|https://frl.publisso.de/adhoc/uri/Um9zYWxlcywgSXZ5IEEu|https://frl.publisso.de/adhoc/uri/VG9sa29mZi1SdWJpbiwgTmluYQ==|https://frl.publisso.de/adhoc/uri/UGFzY3VhbCwgTWFudWVs
1000 Hinweis
  • DeepGreen-ID: b4b80da47be4460cbfcd608ca3bdbe98 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6479598.rdf
1000 Erstellt am 2024-05-21T22:46:46.491+0200
1000 Erstellt von 322
1000 beschreibt frl:6479598
1000 Zuletzt bearbeitet 2024-05-22T14:05:04.328+0200
1000 Objekt bearb. Wed May 22 14:05:04 CEST 2024
1000 Vgl. frl:6479598
1000 Oai Id
  1. oai:frl.publisso.de:frl:6479598 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source